Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Eli Lilly and Company
Age
20–64
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Are overtly healthy Japanese (first generation) or Caucasian males or females, as determined by medical history and physical examination
Have a body mass index of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive
You may not be if
Have known allergies to lasmiditan, related compounds or any components of the formulation of lasmiditan
Have previously received the investigational product in this study, withdrawn from this study, or received lasmiditan in any other study investigating lasmiditan
Have an abnormal supine blood pressure at screening.
Have a history of syncope, presyncope, uncontrolled vertigo, postural dizziness, or a risk of falls, as judged to be clinically significant by the investigator, or have orthostatic decreases in supine blood pressure of \>20 millimeters of mercury (mmHg), or have orthostatic decreases in diastolic blood pressure of \>10 mmHg at screening.
Are women who are pregnant, lactating, or have a positive pregnancy test at screening or admission to the clinical research unit (CRU)
Have donated blood of more than 500 milliliters (mL) within 1 month prior to screening
Clareo Health | A Study of Lasmiditan in Healthy Japanese and Caucasian Participants
